stockportfolio.pro
Stocks / CAI vs CGON
CAI vs CGON
Caris Life Sciences, Inc. and CG Oncology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Caris Life Sciences, Inc. (CAI) | CG Oncology, Inc. (CGON) | |
|---|---|---|
| Market cap | $5.0B | $5.1B |
| Revenue (latest FY) | $812.03M | $4.04M |
| Net income (latest FY) | $-68.09M | $-161.00M |
| Revenue growth (5y CAGR) | 46.5% | 176.6% |
| Net margin | -8.4% | -3985.0% |
| Return on equity | -11.8% | -21.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CAI — free Open CGON — freeFrequently asked questions
Which is bigger, CAI or CGON?
CG Oncology, Inc. is larger by market capitalization — $5.1B versus $5.0B.
Which grows faster, CAI or CGON?
Over the last five fiscal years, CG Oncology, Inc. grew revenue faster — 176.6%/yr versus 46.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.